Influenza Antigens NP and M2 Confer Cross Protection to BALB/c Mice against Lethal Challenge with H1N1, Pandemic H1N1 or H5N1 Influenza A Viruses.
Animals
Antibodies, Viral
/ blood
Antigens, Viral
/ immunology
Cross Protection
Female
Genetic Vectors
Influenza A Virus, H1N1 Subtype
/ immunology
Influenza A Virus, H5N1 Subtype
/ immunology
Influenza Vaccines
/ administration & dosage
Mice, Inbred BALB C
Nucleocapsid Proteins
/ administration & dosage
Orthomyxoviridae Infections
/ immunology
Pandemics
Vaccination
Viral Matrix Proteins
/ administration & dosage
Viroporin Proteins
/ administration & dosage
conserved antigens
hemagglutinin
influenza A
matrix protein 1
matrix protein 2
modified Vaccinia virus Ankara (MVA)
nucleoprotein
vaccine
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
27 08 2021
27 08 2021
Historique:
received:
09
07
2021
revised:
24
08
2021
accepted:
26
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
10
2
2022
Statut:
epublish
Résumé
Influenza hemagglutinin (HA) is considered a major protective antigen of seasonal influenza vaccine but antigenic drift of HA necessitates annual immunizations using new circulating HA versions. Low variation found within conserved non-HA influenza virus (INFV) antigens may maintain protection with less frequent immunizations. Conserved antigens of influenza A virus (INFV A) that can generate cross protection against multiple INFV strains were evaluated in BALB/c mice using modified Vaccinia virus Ankara (MVA)-vectored vaccines that expressed INFV A antigens hemagglutinin (HA), matrix protein 1 (M1), nucleoprotein (NP), matrix protein 2 (M2), repeats of the external portion of M2 (M2e) or as tandem repeats (METR), and M2e with transmembrane region and cytoplasmic loop (M2eTML). Protection by combinations of non-HA antigens was equivalent to that of subtype-matched HA. Combinations of NP and forms of M2e generated serum antibody responses and protected mice against lethal INFV A challenge using PR8, pandemic H1N1 A/Mexico/4108/2009 (pH1N1) or H5N1 A/Vietnam/1203/2004 (H5N1) viruses, as demonstrated by reduced lung viral burden and protection against weight loss. The highest levels of protection were obtained with NP and M2e antigens delivered as MVA inserts, resulting in broadly protective immunity in mice and enhancement of previous natural immunity to INFV A.
Identifiants
pubmed: 34578289
pii: v13091708
doi: 10.3390/v13091708
pmc: PMC8473317
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Antigens, Viral
0
Influenza Vaccines
0
M2 protein, Influenza A virus
0
NP protein, Influenza A virus
0
Nucleocapsid Proteins
0
Viral Matrix Proteins
0
Viroporin Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Références
Emerg Infect Dis. 2006 Apr;12(4):569-74
pubmed: 16704803
J Immunol. 1989 Nov 1;143(9):3007-14
pubmed: 2478631
J Immunol. 2011 Apr 1;186(7):4331-9
pubmed: 21357542
Clin Microbiol Infect. 2017 Apr;23(4):222-228
pubmed: 28216325
Immunol Lett. 1993 Jun;36(3):305-12
pubmed: 8370602
Cell Cycle. 2010 Mar 1;9(5):958-70
pubmed: 20160492
J Virol. 1993 May;67(5):2723-9
pubmed: 8474171
J Med Virol. 2014 Jun;86(6):995-1002
pubmed: 24136709
Antiviral Res. 2013 Sep;99(3):328-35
pubmed: 23811283
PLoS One. 2013 Sep 25;8(9):e75460
pubmed: 24086536
Vaccine. 2015 Aug 20;33(35):4349-58
pubmed: 26048779
Clin Infect Dis. 2012 Jul;55(1):19-25
pubmed: 22441650
Viruses. 2014 Jul 17;6(7):2735-61
pubmed: 25036462
Vaccine. 2008 Jan 10;26(2):201-14
pubmed: 18063235
PLoS One. 2014 Feb 11;9(2):e88340
pubmed: 24523886
J Virol. 2013 May;87(10):5985-93
pubmed: 23514880
Vaccine. 2005 Nov 16;23(46-47):5404-10
pubmed: 16011865
J Virol Methods. 2008 Feb;147(2):265-74
pubmed: 18006085
Vaccine. 1995 Oct;13(14):1353-9
pubmed: 8585293
J Virol Methods. 2008 Dec;154(1-2):121-7
pubmed: 18789973
PLoS Pathog. 2013 Jan;9(1):e1003104
pubmed: 23300455
Bioinformatics. 2013 Aug 1;29(15):1904-7
pubmed: 23716197
J Virol. 1992 Feb;66(2):1129-38
pubmed: 1731092
Clin Exp Vaccine Res. 2014 Jan;3(1):12-28
pubmed: 24427759
Biomed Res Int. 2013;2013:686549
pubmed: 23984396
Vaccine. 2012 Oct 12;30(46):6527-33
pubmed: 22959982
J Virol. 1991 Oct;65(10):5491-8
pubmed: 1895397
PLoS One. 2014 Sep 17;9(9):e107316
pubmed: 25229722
Vaccines (Basel). 2019 Mar 22;7(1):
pubmed: 30909516
J Virol. 1994 Jun;68(6):3505-11
pubmed: 7514677
FEMS Immunol Med Microbiol. 2008 Jun;53(1):79-84
pubmed: 18400009
Lancet Infect Dis. 2012 Jan;12(1):36-44
pubmed: 22032844
Immunology. 2002 Feb;105(2):204-12
pubmed: 11872096
PLoS One. 2012;7(12):e52488
pubmed: 23285063
PLoS One. 2012;7(10):e48322
pubmed: 23118984
PLoS One. 2013;8(3):e55435
pubmed: 23536756
Immunogenetics. 1987;26(4-5):267-72
pubmed: 2443447
J Clin Invest. 2008 Oct;118(10):3478-90
pubmed: 18802496
Hum Vaccin Immunother. 2013 Jul;9(7):1598-607
pubmed: 23846304
Sci Rep. 2013;3:1443
pubmed: 23485942
Viruses. 2014 Apr 29;6(5):1974-91
pubmed: 24784572
Nanomedicine. 2014 Feb;10(2):473-82
pubmed: 23988715
Adv Virus Res. 2017;97:187-243
pubmed: 28057259
J Virol. 2006 Jul;80(13):6318-23
pubmed: 16775319
Proc Natl Acad Sci U S A. 1993 May 1;90(9):4171-5
pubmed: 8387212
Immunogenetics. 1995;41(4):178-228
pubmed: 7890324
Immunol Lett. 2004 May 15;93(2-3):131-6
pubmed: 15158608
Virol J. 2012 Dec 29;9:322
pubmed: 23272943
Virus Genes. 2000 Oct;21(3):157-65
pubmed: 11129631
Clin Infect Dis. 2011 Dec;53(12):1179-87
pubmed: 21976461
Vaccine. 2007 Sep 28;25(39-40):6845-51
pubmed: 17728024
Cell. 1988 Jan 29;52(2):253-8
pubmed: 2449284
Virology. 2017 Sep;509:82-89
pubmed: 28622575
J Exp Med. 2014 Jul 28;211(8):1637-55
pubmed: 25002751
Vaccine. 2013 Apr 3;31(14):1848-55
pubmed: 23376279